Evaluation of contrast-enhanced ultrasound for predicting tumor grade in small (≤4 cm) clear cell renal cell carcinoma: Qualitative and quantitative analysis
Restricted accessResearch articleFirst published online December 3, 2024
Evaluation of contrast-enhanced ultrasound for predicting tumor grade in small (≤4 cm) clear cell renal cell carcinoma: Qualitative and quantitative analysis
The study aimed to evaluate the utility of qualitative and quantitative analysis employing contrast-enhanced ultrasound (CEUS) in predicting the WHO/ISUP grade of small (≤4 cm) clear cell renal cell carcinoma (ccRCCs).
METHODS:
Patients with small ccRCCs, confirmed by histological examination, underwent preoperative CEUS and were classified into low- (grade I/II) and high-grade (grade III/IV) groups. Qualitative and quantitative assessments of CEUS were conducted and compared between the two groups. Diagnostic performance was assessed using receiver operating characteristic curves.
RESULTS:
A total of 72 patients were diagnosed with small ccRCCs, comprising 23 individuals in the high-grade group and 49 in the low-grade group. The low-grade group exhibited a significantly greater percentage of hyper-enhancement compared to the high-grade group (79.6% VS 39.1%, P < 0.05). The low-grade group showed significantly higher relative index values for peak enhancement, wash-in area under the curve, wash-in rate, wash-in perfusion index, and wash-out rate compared to the high-grade group (all P < 0.05). The AUC values for qualitative and quantitative parameters in predicting the WHO/ISUP grade of small ccRCCs ranged from 0.676 to 0.756.
CONCLUSIONS:
Both qualitative and quantitative CEUS analysis could help to distinguish the high- from low-grade small ccRCCs.
SanchezA, FeldmanAS, HakimiAA. Current management of small renal masses, including patient selection, renal tumor biopsy, active surveillance, and thermal ablation. J Clin Oncol. 2018;36(36):3591–600.
2.
NguyenMM, GillIS, EllisonLM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol. 2006;176(6 Pt 1):2397–400, 2400.
3.
HeW, LiuZ, TianY, LiY, XuC, XiaoR, et al.Predictive Factors Affecting Metastasis of Small Renal Mass and Its Prognostic Analysis. Clin Med Insights Oncol. 2022;16:1363196285.
4.
ZnaorA, Lortet-TieulentJ, LaversanneM, JemalA, BrayF. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–30.
5.
UmbreitEC, ShimkoMS, ChildsMA, LohseCM, ChevilleJC, LeibovichBC, et al.Metastatic potential of a renal mass according to original tumour size at presentation. Bju Int. 2012;109(2):190–4, 194.
LebretT, PoulainJE, MolinieV, HerveJM, DenouxY, GuthA, et al.Percutaneous core biopsy for renal masses: indications, accuracy and results. J Urol. 2007;178(4 Pt 1):1184–8, 1188.
8.
LeveridgeMJ, FinelliA, KachuraJR, EvansA, ChungH, ShiffDA, et al.Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol. 2011;60(3):578–84.
9.
HalversonSJ, KunjuLP, BhallaR, GadzinskiAJ, AldermanM, MillerDC, et al.Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology. J Urol. 2013;189(2):441–6.
10.
RousselE, CapitanioU, KutikovA, OosterwijkE, PedrosaI, RoweSP, et al.Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. Eur Urol. 2022;81(5):476–88.
11.
LiuQ, GongH, ChenQ, YuanC, HuB. Clinical Application Value of Contrast-Enhanced Ultrasound in the Diagnosis of Renal Space-Occupying Lesions. Int J Nephrol Renovasc Dis. 2023;16:253–9.
12.
DasCJ, AgarwalK, SharmaS, SethA. Role of Contrast-Enhanced Ultrasound in Evaluation of Cystic Renal Mass. J Ultrasound Med. 2023;42(12):2873–81.
13.
JungEM, StroszczynskiC, JungF. Advanced multimodal imaging of solid thyroid lesions with artificial intelligence-optimized B-mode, elastography, and contrast-enhanced ultrasonography parametric and with perfusion imaging: Initial results. Clin Hemorheol Microcirc. 2023;84(2):227–36.
14.
SidhuPS, CantisaniV, DietrichCF, GiljaOH, SaftoiuA, BartelsE, et al.The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall Med. 2018;39(2):e2–44.
15.
RenL, ZhaoY, XiaoJ, LiM, ZhangY, ZhuL, et al.Contrast-enhanced ultrasound in evaluating the severity of acute kidney injury: An animal experimental study. Clin Hemorheol Microcirc. 2023;85(4):447–58.
16.
PutzFJ, ErlmeierA, WiesingerI, VerlohN, StroszczynskiC, BanasB, et al.Contrast-enhanced ultrasound (CEUS) in renal imaging at an interdisciplinary ultrasound centre: Possibilities of dynamic microvascularisation and perfusion. Clin Hemorheol Microcirc. 2017;66(4):293–302.
17.
HeM, GaoQ, XiangJ, MaoQ, JiangT. Diagnostic Value of Qualitative and Quantitative Contrast-Enhanced Ultrasound for Pathological Subtypes of Small Solid Renal Masses. J Ultrasound Med. 2023.
18.
LiuH, CaoH, ChenL, FangL, LiuY, ZhanJ, et al.The quantitative evaluation of contrast-enhanced ultrasound in the differentiation of small renal cell carcinoma subtypes and angiomyolipoma. Quant Imaging Med Surg. 2022;12(1):106–18.
19.
HuangX, NieF, ZhuJ, LiuL, WangN. Diagnostic Value of Contrast-Enhanced Ultrasound Features for WHO/ISUP Grading in Renal Cell Carcinoma. J Ultrasound Med. 2023.
20.
MengX, YangR, ZhaoS, SunZ, WangH. Associations between tumor grade, contrast-enhanced ultrasound features, and microvascular density in patients with clear cell renal cell carcinoma: a retrospective study. Quant Imaging Med Surg. 2022;12(3):1882–92.
21.
JiangJ, ChenY, ZhouY, ZhangH. Clear cell renal cell carcinoma: contrast-enhanced ultrasound features relation to tumor size. Eur J Radiol. 2010;73(1):162–7.
22.
PatelBN, BibbeyA, ChoudhuryKR, LederRA, NelsonRC, MarinD. Characterization of Small (<4cm) Focal Renal Lesions: Diagnostic Accuracy of Spectral Analysis Using Single-Phase Contrast-Enhanced Dual-Energy CT. AJR Am J Roentgenol. 2017;209(4):815–25.
23.
LudwigDR, BallardDH, ShettyAS, SiegelCL, YanoM. Apparent Diffusion Coefficient Distinguishes Malignancy in T1-Hyperintense Small Renal Masses. AJR Am J Roentgenol. 2020;214(1):114–21.
24.
LiH, LiA, ZhuH, HuY, LiJ, XiaL, et al.Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Differentiation of Minimal Fat Angiomyolipoma from Clear Cell Renal Cell Carcinoma. Acad Radiol. 2019;26(5):632–9.
25.
ParkJJ, KimCK. Small (<4cm) Renal Tumors With Predominantly Low Signal Intensity on T2-Weighted Images: Differentiation of Minimal-Fat Angiomyolipoma From Renal Cell Carcinoma. AJR Am J Roentgenol. 2017;208(1):124–30.
26.
MytsykY, DutkaI, YuriyB, MaksymovychI, CaprndaM, GazdikovaK, et al.Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI. Int Urol Nephrol. 2018;50(2):197–204.
27.
SinghalT, SinghP, ParidaGK, AgrawalK. Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis. Ann Nucl Med. 2024;38(3):176–87.
28.
CaoH, FangL, ChenL, ZhanJ, DiaoX, LiuY, et al.The Value of Contrast-Enhanced Ultrasound in Diagnosing Small Renal Cell Carcinoma Subtypes and Angiomyolipoma. J Ultrasound Med. 2022;41(6):1415–23.
29.
LiuH, CaoH, ChenL, FangL, LiuY, ZhanJ, et al.The quantitative evaluation of contrast-enhanced ultrasound in the differentiation of small renal cell carcinoma subtypes and angiomyolipoma. Quant Imaging Med Surg. 2022;12(1):106–18.
30.
DagherJ, DelahuntB, Rioux-LeclercqN, EgevadL, SrigleyJR, CoughlinG, et al.Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology. 2017;71(6):918–25.
31.
FernandezT, SebastiaC, PanoB, CorominasMD, VasD, Garcia-RochC, et al.Contrast-enhanced US in Renal Transplant Complications: Overview and Imaging Features. Radiographics. 2024;44(6):e230182.
32.
PsenicnyE, GlusicM, PokornM, KljucevsekD. Contrast-enhanced ultrasound in detection and follow-up of focal renal infections in children. Br J Radiol. 2022;95(1140):20220290.
33.
MollerK, LoweA, JenssenC, ChaubalN, GottschallH, MisselwitzB, et al.Comments and Illustrations of Ultrasound Findings in Extrapulmonary Tuberculosis Manifestations. Diagnostics (Basel). 2024;14(7).
34.
FurrerMA, SpycherS, ButtikerSM, GrossT, BosshardP, ThalmannGN, et al.Comparison of the Diagnostic Performance of Contrast-enhanced Ultrasound with That of Contrast-enhanced Computed Tomography and Contrast-enhanced Magnetic Resonance Imaging in the Evaluation of Renal Masses: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020;3(4):464–73.
35.
WeiS, TianF, XiaQ, HuangP, ZhangY, XiaZ, et al.Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Cancer Imaging. 2019;20(1):1.
36.
MarschnerCA, RuebenthalerJ, SchwarzeV, NegraoDFG, ZhangL, ClevertDA. Comparison of computed tomography (CT), magnetic resonance imaging (MRI) and contrast-enhanced ultrasound (CEUS) in the evaluation of unclear renal lesions. Rofo. 2020;192(11):1053–9.
37.
RubenthalerJ, NegraoDFG, Mueller-PeltzerK, ClevertDA. Evaluation of renal lesions using contrast-enhanced ultrasound (CEUS); a 10-year retrospective European single-centre analysis. Eur Radiol. 2018;28(11):4542–9.
38.
TufanoA, LeonardoC, Di BellaC, LucarelliG, DolcettiV, DipintoP, et al.Qualitative Assessment of Contrast-Enhanced Ultrasound in Differentiating Clear Cell Renal Cell Carcinoma and Oncocytoma. J Clin Med. 2023;12(9).
39.
ZhangX, ZhangG, XuL, BaiX, ZhangJ, ChenL, et al.Prediction of World Health Organization /International Society of Urological Pathology (WHO/ISUP) Pathological Grading of Clear Cell Renal Cell Carcinoma by Dual-Layer Spectral CT. Acad Radiol. 2022.
40.
MaW, YangJ, LiuN, PuX, QuF, XuL, et al.Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?Bmc Cancer. 2020;20(1):1182.
41.
CoyH, YoungJR, DouekML, PantuckA, BrownMS, SayreJ, et al.Association of qualitative and quantitative imaging features on multiphasic multidetector CT with tumor grade in clear cell renal cell carcinoma. Abdom Radiol (NY). 2019;44(1):180–9.
42.
KanZ, PhongkitkarunS, KobayashiS, TangY, EllisLM, LeeTY, et al.Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology. 2005;237(1):151–8.
43.
LinL, WangY, YanL, LiN, TianX, LiQ, et al.Interobserver reproducibility of contrast-enhanced ultrasound in diabetic nephropathy. Br J Radiol2022;95(1129):20210189.
44.
RidolfiF, AbbattistaT, BusilacchiP, BrunelliE. Contrast-enhanced ultrasound evaluation of hepatic microvascular changes in liver diseases. World J Gastroenterol. 2012;18(37):5225–30.
45.
DietrichCF, CorreasJM, CuiXW, DongY, HavreRF, JenssenC, et al.EFSUMB Technical Review - Update Dynamic Contrast-Enhanced Ultrasound (DCE-CEUS) for the Quantification of Tumor Perfusion. Ultraschall Med. 2024;45(1):36–46.
